Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,589,959

« Back to Dashboard

Summary for Patent: 6,589,959

Title: Crystalline bis[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]p yrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt
Abstract:The present invention relates to a crystalline form of the compound bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]p yrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt, as well as processes for its manufacture and pharmaceutical compositions comprising the crystalline form, which is useful as an agent for treating hyperlipidemia, hypercholesterolemia and atherosclerosis.
Inventor(s): Taylor; Nigel P (Macclesfield, GB)
Assignee: Astrazeneca AB (Sodertalje, SE)
Application Number:09/869,462
Patent Claim Types:
see list of patent claims
Compound; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 2nd percentile
Forward Citations: 2nd percentile

No matches for this query

Foreign Priority and PCT Information for Patent: 6,589,959

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9900339Jan 09, 1999
PCT Information
PCT FiledDecember 23, 1999PCT Application Number:PCT/GB99/04439
PCT Publication Date:July 20, 2000PCT Publication Number: WO00/42024

International Patent Family for Patent: 6,589,959

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1144389► subscribe
Poland201800► subscribe
Poland348775► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.